Horizon Therapeutics
Horizon Therapeutics[edit]
Horizon Therapeutics is a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The company is headquartered in Dublin, Ireland, with significant operations in the United States.
History[edit]
Horizon Therapeutics was founded in 2008. Over the years, the company has grown through strategic acquisitions and the development of a robust pipeline of medicines. Horizon has focused on expanding its portfolio to include treatments for rare diseases, which often have limited therapeutic options.
Products[edit]
Horizon Therapeutics has developed a range of products, primarily targeting rare diseases and conditions related to inflammation and autoimmunity. Some of the key products include:
- Tepezza (teprotumumab-trbw) - A treatment for Thyroid Eye Disease (TED), a rare autoimmune condition.
- Krystexxa (pegloticase) - Used for chronic gout in adult patients who are refractory to conventional therapy.
- Ravicti (glycerol phenylbutyrate) - Indicated for the chronic management of urea cycle disorders.
Research and Development[edit]
Horizon Therapeutics invests significantly in research and development to discover new therapies and improve existing ones. The company collaborates with academic institutions, research organizations, and other pharmaceutical companies to advance its scientific goals.
Corporate Social Responsibility[edit]
Horizon is committed to corporate social responsibility, focusing on patient advocacy, community engagement, and environmental sustainability. The company supports various initiatives to improve patient access to medicines and enhance the quality of life for those affected by rare diseases.
Related pages[edit]
| Pharmaceutical companies | ||||||
|---|---|---|---|---|---|---|
|
